Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments

The mechanism of risk reduction obtained by blood pressure‐lowering pharmacological treatment remains unclear. We explored the amount of risk reduction attributable to the apparent effect of antihypertensive medicines on blood pressure by using the capture approach. Five randomized, placebo or nil controlled trials with a total of 28 997 subjects and 1935 cardiovascular fatal or non‐fatal events from the INDANA database met the eligibility criteria. Computations were performed on the original individual records using multiple Cox's proportional hazard regression models designed for meeting the assumed treatment mode of action and comparing relevant assumptions. For coronary event, the results are inconclusive essentially because the risk reduction is mild. However, for stroke the risk reduction adjusted for baseline risk factors is 34% (P < 0.0001). The part explained by the effect of treatment on systolic blood pressure is 49% of this reduction, with 95% confidence interval not including 100%. This result suggests that the apparent effect on blood pressure is not the only cause of stroke risk reduction in hypertensive subjects submitted to an antihypertensive medicine.

[1]  F. Turnbull Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[2]  François Gueyffier,et al.  J-Shaped Relationship between Blood Pressure and Mortality in Hypertensive Patients: New Insights from a Meta-Analysis of Individual-Patient Data , 2002, Annals of Internal Medicine.

[3]  Salim Yusuf,et al.  Blood-pressure reduction and cardiovascular risk in HOPE study , 2001, The Lancet.

[4]  Jan A Staessen,et al.  Cardiovascular protection and blood pressure reduction: a meta-analysis , 2001, The Lancet.

[5]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[6]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[7]  T. Hedner,et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.

[8]  S J Pocock,et al.  Assessing treatment-time interaction in clinical trials with time to event data: a meta-analysis of hypertension trials. , 1998, Statistics in medicine.

[9]  G. Molenberghs,et al.  Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.

[10]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[11]  P. Hartigan,et al.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.

[12]  S. Pocock,et al.  INDANA: a meta-analysis on individual patient data in hypertension. Protocol and preliminary results. , 1995, Therapie.

[13]  B. Dahlöf,et al.  Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) , 1991, The Lancet.

[14]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[15]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[16]  R. Prentice Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[17]  T S Warrender,et al.  Randomised trial of treatment of hypertension in elderly patients in primary care. , 1986, British medical journal.

[18]  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. , 1985, British medical journal.

[19]  C. Bulpitt,et al.  Mortality and Morbidity Results from the European Working Party on High Blood Pressure in the Elderly Trial , 1985, The Lancet.

[20]  J. Abernethy The Australian therapeutic trial in mild hypertension. , 1984, Hypertension.

[21]  A. Doyle,et al.  The Australian Therapeutic Trial in Mild Hypertension. , 1982, Nephron.

[22]  E. Frohlich,et al.  EVALUATION OF DRUG TREATMENT IN MILD HYPERTENSION: VA‐NHLBI FEASIBILITY TRIAL * , 1978, Annals of the New York Academy of Sciences.

[23]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[24]  D. Ruppert,et al.  Measurement Error in Nonlinear Models , 1995 .

[25]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[26]  C. Dollery,et al.  Medical Research Council trial of treatment of hypertension in older adults: principal results. , 1992 .

[27]  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. , 1991, JAMA.

[28]  L H Kuller,et al.  Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. , 1989, Stroke.

[29]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .